Can the Oncotype DX Breast Cancer Assay impact recommendation and receipt of chemotherapy in early stage breast cancer? Does the test also improve patient experience? These were some of the questions asked by researchers at the University of Michigan, and the results presented during the annual meeting of the American Society of Clinical Oncology.
Can the Oncotype DX Breast Cancer Assay, also known as the 21-gene Recurrence Score (RS) assay, impact recommendation and receipt of chemotherapy in early stage breast cancer? Does the test also improve patient experience? These were some of the questions posed by researchers at the University of Michigan, and the results were presented by Steven J. Katz, MD, MPH, during a health policy session at the annual meeting of the American Society of Clinical Oncology, held in Chicago, June 3-7, 2016.
This particular assay, developed by the company Genomic Health, is expected to predict disease recurrence and response to chemotherapy in estrogen receptor (ER)—positive, lymph node–negative early stage breast cancer. According to the company website, the test also predicts the risk of local recurrence in those who have the more common non-invasive form of breast cancer, ductal carcinoma in-situ or DCIS.
Sixty-nine percent of the 3781 women with breast cancer—from the Georgia and Los Angeles SEER registries—approached by Katz and his team, responded to the survey. Katz said that the mean age of the women who participated was older, and they had a wide distribution of age, ethnicity, and income. The women, who had been treated in 2013 and 2014, were asked to answer questions related to their oncologist’s treatment recommendations, chemotherapy receipt, and treatment decision satisfaction. More than 1200 patients with Stage I/II, ER+, HER2- disease were categorized into 3 groups:
The regression analysis conducted on this data was adjusted for comorbidity, education, income, race, location, and sampling design.1
Katz showed that in the sample of women who were evaluated, recommendations for chemotherapy, and receipt of chemotherapy, were both in line with their risk scores: a majority of those tested received a recommendation for, and subsequent chemotherapy treatment (see table below). “While a majority of tested patients, about 75%, reported that the test helped decision making yet a small percentage [25%] did not recall their test status,” Katz said.
Node negative, favorable (n = 718)
Node negative, unfavorable (n = 283)
Node positive,
(n = 286)
Recommended Against/neutral/for
Got chemo
Recommended Against/neutral/for
Got chemo
Recommended Against/neutral/for
Got chemo
No test (608)
54/21/25
14
25/9/66
59
9/9/82
83
RS
0-17 (427)
78/10/12
3
64/11/25
6
49/12/39
22
18-30 (204)
38/19/43
38
20/25/55
52
9/22/69
64
>30 (48)
0/0/100
100
3/5/92
94
0/0/200
100
Chemo indicates chemotherapy; RS, recurrence score.
Katz believes that the RS assay is genuinely concordant with node-negative disease, and test uptake is substantial even in patients with node-positive disease. “Patients seem to shift toward less chemotherapy, rather than more treatment, following RS score,” he said, adding that the effect was most evident in women with less favorable prognosis.
“The TAILORx and RxPONDER trials will refine the treatment algorithms further, following the test for recurrence score,” Katz said.
Reference
Katz SJ, Friese CR, Li Y, et al. Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer. J Clin Oncol. 2016;34 (suppl; abstract 6501).
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More